Staphylococcus aureus is the deadliest of all the common Staphylococcal bacteria and is regarded as one of the most common bacteria that cause illnesses. S. aureus's ability to build biofilms and other virulence variables determines whether it can cause superficial or invasive infections. It can also rapidly alter its virulence and metabolic responses in various tissues. Anti-virulent medications that stop the development of biofilms and virulence factors are therefore becoming increasingly necessary. As a result, we focused on an antibiotic that had already been approved and investigated whether changing the dosage would have an impact on S. aureus virulence. Most of the studied isolates exhibited a noteworthy decrease in S. aureus biofilm and virulence factors production (protease, hemolysin, and coagulase) upon treatment with 1/4 and 1/8 MICs of ceftriaxone, according to the data. It might therefore be regarded as a survival strategy to enhance patient outcomes and reduce germ resistance